Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.36 |
| ▸ | ACP1 | P24666 | 4/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 3/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648937 | 0.94 | KMT2A (0.36) | PTPN1ACP1HDAC6ALDH1A1EP300 | |
| SCHEMBL5648860 | 0.91 | PTPN1 (0.35) | PTPN1ACP1HDAC6EP300CTRB1 | |
| SCHEMBL5649416 | 0.91 | MEN1 (0.37) | PTPN1ACP1HDAC6EP300KMT2A | |
| SCHEMBL5648344 | 0.89 | KMT2A (0.35) | PTPN1ACP1HDAC6ALDH1A1EP300 | |
| SCHEMBL5645643 | 0.86 | PTPN1 (0.36) | PTPN1ACP1HDAC6EP300KMT2A | |
| SCHEMBL5647686 | 0.82 | PLAU (0.42) | HDAC6CTRB1 | |
| SCHEMBL5651384 | 0.81 | AKR1B1 (0.37) | PTPN1ACP1HDAC6CTRB1KMT2A | |
| SCHEMBL5648228 | 0.81 | PTPN1 (0.40) | PTPN1ACP1HDAC6KMT2APTPN2 | |
| SCHEMBL5649247 | 0.81 | PTPN1 (0.44) | PTPN1ACP1HDAC6CTRB1KMT2A | |
| SCHEMBL5652364 | 0.80 | CTRB1 (0.39) | PTPN1ACP1HDAC6ALDH1A1CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | US | claimed |
| US-7053112-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-30 | — | — | US | claimed |
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | claimed |
| US-7199146-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | US | disclosed |
| US-7053112-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-30 | — | — | US | disclosed |
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SERPINC1, F2, BDKRB1 | PTPN1 1843/4885ACP1 1675/4885HDAC6 172/4885 |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SERPINC1, F2, BDKRB1 | PTPN1 1936/4885ACP1 2051/4885HDAC6 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.